Danish Drugmaker to Continue Selling Controversial Anesthetic in United States

Danish drugmaker H. Lundbeck announced Wednesday that it will keep selling its Nembutal anesthetic in the United States, despite the fact that it opposes the use of the drug in lethal injection executions, according to a Wall Street Journal report.

Nembutal is designed to treat epileptic seizures and is sometimes used to euthanize animals. While the drug is not designed for prison executions, Nembutal is increasingly used in U.S. executions.

Ulf Wiinberg, CEO of Lundbeck, said the company is working to prevent the drug's use in lethal injection executions. He said the Lundback would like to manage the drug's distribution in the U.S. to ensure patient access while also preventing misuse.

Nembutal represents less than 1 percent of sales for Lundbeck and was acquired when the company purchased U.S.-based firm Ovation in 2009.

Read the Wall Street Journal report on Nembutal.

Related Articles on Anesthesia:
Webinar Discusses Benefits and Challenges of Changing Anesthesia Providers
Anesthesiologist Reaches Settlement With Former Practice Over Breach of Contract
Supreme Court Declines to Hear Case Involving Patient Death From Nurse Anesthetist Malpractice

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast